FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132988399> ?p ?o ?g. }

• W3132988399 endingPage "307" @default.
• W3132988399 startingPage "297" @default.
• W3132988399 abstract "Abstract Purpose Placental therapeutics aim to treat placental disease; however, ethical and regulatory issues should be considered if the drug also potentially affects the fetus. Drugs that might transfer or edit genes carry a specific challenge because currently fetal gene editing and fetal gene therapy are considered unethical. Methods This article reviews the literature on ethical and regulatory considerations for placental therapeutics. Findings Proposals for maternal gene therapy, directed to the maternal side of the placenta, have been discussed with patients and stakeholders. No absolute ethical, legal, or regulatory barriers to this potential treatment were identified. Patients who have experienced placental disease, such as fetal growth restriction, are interested in these therapies; some would participate in first-in-human trials. Such trials need careful regulatory considerations, such as the steps required to indicate tolerability and efficacy in preclinical models and the optimal animals for reproductive toxicology studies. Ex vivo dual human placenta perfusion experiments and villous explant in vitro studies allow drugs to be tested in normal and diseased human placenta, providing short-term tolerability and toxicologic assessment. Testing drugs in nonhuman primates is an option but carries ethical and feasibility considerations. Selection of inclusion and exclusion criteria for clinical trial participants is important to ensure that the most suitable patients are exposed to a first-in-human drug. These patients will almost certainly be pregnant women with a high risk of perinatal loss and/or perinatal and maternal morbidity. Criteria should identify sufficient numbers of patients to make a trial feasible as well as a phenotype that will respond to the mechanism of action. How to dose escalate and to capture information on adverse events are also key to optimal clinical trial design. Implications Developing placental therapeutics requires input from scientists, practitioners, and regulators and close liaison with patients to ensure that new drugs are tested as carefully as possible." @default.
• W3132988399 created "2021-03-01" @default.
• W3132988399 creator A5055496507 @default.
• W3132988399 date "2021-02-01" @default.
• W3132988399 modified "2023-10-16" @default.
• W3132988399 title "Ethical and Regulatory Considerations of Placental Therapeutics" @default.
• W3132988399 cites W1757974377 @default.
• W3132988399 cites W1970366126 @default.
• W3132988399 cites W1977128767 @default.
• W3132988399 cites W2006245385 @default.
• W3132988399 cites W2042551148 @default.
• W3132988399 cites W2052581114 @default.
• W3132988399 cites W2057159511 @default.
• W3132988399 cites W2077204318 @default.
• W3132988399 cites W2077387106 @default.
• W3132988399 cites W2098117143 @default.
• W3132988399 cites W2135796748 @default.
• W3132988399 cites W2186799933 @default.
• W3132988399 cites W2296341478 @default.
• W3132988399 cites W2462243653 @default.
• W3132988399 cites W2539312529 @default.
• W3132988399 cites W2548146385 @default.
• W3132988399 cites W2580657348 @default.
• W3132988399 cites W2736103765 @default.
• W3132988399 cites W2760302655 @default.
• W3132988399 cites W2768230267 @default.
• W3132988399 cites W2773654608 @default.
• W3132988399 cites W2794106594 @default.
• W3132988399 cites W2884281315 @default.
• W3132988399 cites W2906276280 @default.
• W3132988399 cites W2923783964 @default.
• W3132988399 cites W2964725333 @default.
• W3132988399 cites W2967819890 @default.
• W3132988399 cites W2973923778 @default.
• W3132988399 cites W2991962512 @default.
• W3132988399 cites W3093010777 @default.
• W3132988399 cites W4210702104 @default.
• W3132988399 doi "https://doi.org/10.1016/j.clinthera.2021.01.003" @default.
• W3132988399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33610291" @default.
• W3132988399 hasPublicationYear "2021" @default.
• W3132988399 type Work @default.
• W3132988399 sameAs 3132988399 @default.
• W3132988399 citedByCount "2" @default.
• W3132988399 countsByYear W31329883992021 @default.
• W3132988399 countsByYear W31329883992022 @default.
• W3132988399 crossrefType "journal-article" @default.
• W3132988399 hasAuthorship W3132988399A5055496507 @default.
• W3132988399 hasBestOaLocation W31329883991 @default.
• W3132988399 hasConcept C71924100 @default.
• W3132988399 hasConceptScore W3132988399C71924100 @default.
• W3132988399 hasIssue "2" @default.
• W3132988399 hasLocation W31329883991 @default.
• W3132988399 hasLocation W31329883992 @default.
• W3132988399 hasLocation W31329883993 @default.
• W3132988399 hasOpenAccess W3132988399 @default.
• W3132988399 hasPrimaryLocation W31329883991 @default.
• W3132988399 hasRelatedWork W1506200166 @default.
• W3132988399 hasRelatedWork W2039318446 @default.
• W3132988399 hasRelatedWork W2048182022 @default.
• W3132988399 hasRelatedWork W2080531066 @default.
• W3132988399 hasRelatedWork W2604872355 @default.
• W3132988399 hasRelatedWork W2748952813 @default.
• W3132988399 hasRelatedWork W2899084033 @default.
• W3132988399 hasRelatedWork W2998699411 @default.
• W3132988399 hasRelatedWork W3032375762 @default.
• W3132988399 hasRelatedWork W3108674512 @default.
• W3132988399 hasVolume "43" @default.
• W3132988399 isParatext "false" @default.
• W3132988399 isRetracted "false" @default.
• W3132988399 magId "3132988399" @default.
• W3132988399 workType "article" @default.